company background image
524652 logo

Ind-Swift BSE:524652 Stock Report

Last Price

₹21.44

Market Cap

₹1.2b

7D

-7.0%

1Y

155.8%

Updated

23 Apr, 2024

Data

Company Financials

524652 Stock Overview

Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India.

524652 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health0/6
Dividends0/6

Ind-Swift Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ind-Swift
Historical stock prices
Current Share Price₹21.44
52 Week High₹31.09
52 Week Low₹7.75
Beta-0.25
1 Month Change16.84%
3 Month Change19.05%
1 Year Change155.85%
3 Year Change420.39%
5 Year Change348.54%
Change since IPO91.09%

Recent News & Updates

Recent updates

Shareholder Returns

524652IN PharmaceuticalsIN Market
7D-7.0%-0.5%1.4%
1Y155.8%55.3%46.1%

Return vs Industry: 524652 exceeded the Indian Pharmaceuticals industry which returned 53.7% over the past year.

Return vs Market: 524652 exceeded the Indian Market which returned 45% over the past year.

Price Volatility

Is 524652's price volatile compared to industry and market?
524652 volatility
524652 Average Weekly Movement13.2%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.8%
10% most volatile stocks in IN Market10.1%
10% least volatile stocks in IN Market4.2%

Stable Share Price: 524652's share price has been volatile over the past 3 months.

Volatility Over Time: 524652's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
19831,200Gopal Munjalwww.indswiftltd.com

Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynaecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-allergic, neurology, and oncology. The company also provides Ayurvedic products, as well as contract research and manufacturing services.

Ind-Swift Limited Fundamentals Summary

How do Ind-Swift's earnings and revenue compare to its market cap?
524652 fundamental statistics
Market cap₹1.16b
Earnings (TTM)₹297.88m
Revenue (TTM)₹4.73b

3.9x

P/E Ratio

0.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
524652 income statement (TTM)
Revenue₹4.73b
Cost of Revenue₹2.71b
Gross Profit₹2.02b
Other Expenses₹1.72b
Earnings₹297.88m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)5.50
Gross Margin42.73%
Net Profit Margin6.30%
Debt/Equity Ratio-136.8%

How did 524652 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.